Botanical species · safety record

Borago officinalis

The EFSA Compendium of Botanicals holds 9 constituent measurements for Borago officinalis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Borago officinalis L.

9Constituent measurements

0Safety records

5Cited sources

727Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 727 licensed products naming Borago officinalis as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Aerial parts
Borage seed oil
Borago officinalis
Borago officinalis - seed
Clupeidae - Whole
Fish oil
Grain
Grain(s)

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
2-pentylfuran	Seed	Solvent extraction	1.9 Percent Area	GC-MS	Resolve DOI
Berberine	Flower	Solvent extraction	0.003534 Percent	Phytochemical screening	Resolve DOI
Furfural	Seed	Solvent extraction	1.8 Percent Area	GC-MS	Resolve DOI
Pyrrolizidine alkaloids	Seed	—	≤ 0.5 Microgram/kilogram	HPLC with standard detection methods	Resolve DOI
Pyrrolizidine alkaloids	Unspecified	—	—	Unspecified	Resolve DOI
Sanguinarine	Flower	Solvent extraction	0.01174 Percent	Phytochemical screening	Resolve DOI
Saponins	Flower	Solvent extraction	6.451 Milligram/100 gram	Phytochemical screening	Resolve DOI
Pyrrolizidine alkaloids	Seed	Solvent extraction	0.08 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Pyrrolizidine alkaloids	Stem / stalk	Solvent extraction	0.07 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

These, Anja., Bodi, Dorina., Ronczka, Stefan., Lahrssen-Wiederholt, Monika., Preiss-Weigert, Angelika. Structural screening by multiple reaction monitoring as a new approach for tandem mass spectrometry: presented for the determination of pyrrolizidine alkaloids in plants. Analytical and bioanalytical chemistry, 2013, vol. 405, no. 29, p. 9375-9383.
Cramer, Luise., Fleck, Gunther., Horn, Gert., Beuerle, Till. Process Development of Lappula squarrosa Oil Refinement: Monitoring of Pyrrolizidine Alkaloids in Boraginaceae Seed Oils. JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 2014, vol. 91, no. 5, p. 721-731. DOI
Wu, Shimin., Xu, Ting., Huang, Danfeng. Chemical compositions of the volatile extracts from seeds of Dendranthema nankingense and Borago officinalis . Journal of food and drug analysis, 2015, vol. 23, no. 2, p. 253-259. DOI
Mohajer, Sadegh., Taha, Rosna Mat., Bin Ramli, Rosli., Mohajer, Minoo. Phytochemical constituents and radical scavenging properties of Borago officinalis and Malva sylvestris . Industrial crops and products, 2016, vol. 94, p. 673-681. DOI
Roeder, E., Wiedenfeld, H., Edgar, J. A. Pyrrolizidine alkaloids in medicinal plants from North America. Pharmazie, 2015, vol. 70, no. 6, p. 357-367. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature